History
Ipamorelin was developed in the 1990s during research into secretagogue-type peptides. Unlike earlier compounds such as GHRP-6, Ipamorelin demonstrated greater selectivity, activating target pathway signaling with minimal off-target interference. Since its discovery, it has been applied in studies investigating pituitary signaling, endocrine cascades, and downstream pathway dynamics in laboratory models.
Ipamorelin Structure
CAS #: 170851-70-4
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.9 g/mol
PubChem ID: 9831659
Research Findings
Ipamorelin has been studied in endocrine, metabolic, and regenerative models, with research highlighting its activity in stimulating growth hormone release, modulating IGF-1 pathways, and supporting tissue recovery processes. Studies have also examined its role in metabolic regulation, energy balance, and cellular repair in preclinical systems.
Key Areas of Research:
-
Endocrine: Somatotroph axis, signaling, cascades
-
Signaling: Systemic markers, pathway dynamics
-
Molecular: Remodeling, proliferation, viability
Together, these findings suggest experimental utility for Ipamorelin across multiple biological pathways. By influencing endocrine signaling and downstream remodeling processes, Ipamorelin provides a versatile platform for research into pathway dynamics, endocrine activity, and systemic resilience in laboratory settings.




Reviews
There are no reviews yet.